Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?

Publisher： John Wiley & Sons Inc

E-ISSN： 1099-1557|24|7|709-715

ISSN： 1053-8569

Source： PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol.24, Iss.7, 2015-07, pp. : 709-715

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical and Regulatory Features of Drugs Not Initially Approved by the FDA

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 94, Iss. 6, 2013-12 ,pp. : 670-677

John Wiley & Sons Inc

Access to resources Recommend Favorite

Regulatory review time and post‐market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross‐sectional study

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 306-5251, Iss. 4, 2015-10 ,pp. : 716-726

John Wiley & Sons Inc

Access to resources Recommend Favorite

Regulatory review time and post‐market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross‐sectional study

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 80, Iss. 4, 2015-10 ,pp. : 716-726

John Wiley & Sons Inc

Access to resources Recommend Favorite

Topiramate's effects on alcohol use similar to FDA‐approved drugs

By  

THE BROWN UNIVERSITY PSYCHOPHARMACOLOGY UPDATE, Vol. 26, Iss. 5, 2015-05 ,pp. : 3-4

John Wiley & Sons Inc

Access to resources Recommend Favorite

Some Non‐FDA Approved Uses for Neuromodulation: A Review of the Evidence

By  

PAIN PRACTICE, Vol. 16, Iss. 7, 2016-09 ,pp. : 935-947

John Wiley & Sons Inc

Access to resources Recommend Favorite